Ledger · 2026-09-04 · Biomedical Engineering
Thermoresponsive In-Situ Gelling Biogel via Polyacrylamide/Gelatin Co-Polymerization
Rejected
This concept did not clear the framework. The reasoning is published in full below.
What the assessment found
| Incumbent benchmark | Weaver Ten20 Conductive Paste |
| Entry application | long-term continuous ambulatory EEG monitoring |
| Measured advantage | 2.36x SNR improvement (25.2 dB vs 10.64 dB) and >4.8x impedance reduction (310 Ω vs 1.5–5.0 kΩ) |
| Time to first revenue | 16 months |
| Gross margin at parity | 87.2% |
| Startup CapEx | $215,000 |
| Payback from first sale | 0.3 months |
| Capital productivity | 94.01x |
| Regulatory risk | Moderate — qualification costs reported ($450,000 estimated) |
Why it failed
- Voided by: Form-factor / handling regression, Absence search missing
- Evidence rests on non-peer-reviewed sources
- Absence asserted, search unreported
Assessment
The concept demonstrates clear signal superiority and strong margins, but fails on form factor parity due to requiring refrigerated storage and cold-water/ice removal compared to room-temperature incumbent workflow. Additionally, it lacks a structured Market Absence Ledger section with numeric search counts.
Also flagged
- Price parity asserted, not sourced
- runsheet_no_quantities
A rejection is not a claim that the science is wrong. It means the venture case did not survive: the comparator was not what the buyer actually buys, the comparison was not like-for-like, the advantage fell short of a step change, or the capital and time to first revenue were prohibitive.
Assessed 2026-09-04 against seven gates plus the voiding sub-tests. How the method works · Browse all concepts